Last reviewed · How we verify

NCT04780711

Prevalance of Temporomandibular Joint Disease

Completed Last updated 3 August 2021
What this trial tests

trial in Temporomandibular Joint Disorders in 500 participants. Completed in 1 August 2021.

Timeline
20 March 2021
Primary endpoint
28 July 2021
1 August 2021

Quick facts

Lead sponsorAbant Izzet Baysal University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date20 March 2021
Primary completion28 July 2021
Estimated completion1 August 2021
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Abant Izzet Baysal University

Who can join

Adults 18 to 35, any sex, with Temporomandibular Joint Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Temporomandibular joint (TMJ) disorders are common problems in the society and involve the masticator muscles, jaw joint and related structures. Since TMJ disorders affect functions such as eating and speaking, they can cause important problems in the daily life of the patient. Therefore, its diagnosis and treatment are of great importance. In the treatment of these patients, methods such as analgesic and anti-inflammatory drugs, splint, exercise, physical therapy modalities can be applied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Temporomandibular Joint Disorders

Currently open trials in the same condition.

Other Abant Izzet Baysal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing